List of Acular Ls drug patents

Acular Ls is owned by Allergan.

Acular Ls contains Ketorolac Tromethamine.

Acular Ls has a total of 12 drug patents out of which 0 drug patents have expired.

Acular Ls was authorised for market use on 30 May, 2003.

Acular Ls is available in solution/drops;ophthalmic dosage forms.

Acular Ls can be used as a method of treating ocular pain and/or enhancing ocular comfort, a method of treating ocular pain, a method of treating or preventing ocular pain in a patient, a method of treating or preventing ocular pain and burning, a method of treating or reducing ocular pain and burning/stinging, a method of treating or preventing ocular pain and burning/stinging following corneal surgery, a method of controlling postoperative ocular pain and burning/stinging in a patient.

The generics of Acular Ls are possible to be released after 24 November, 2027.

ACULAR LS Litigations
Can you believe ACULAR LS received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8008338 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8648107 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 2 months from now)

US8377982 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 2 months from now)

US9216167 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 2 months from now)

US8541463 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 2 months from now)

US8207215 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 2 months from now)

US8906950 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 2 months from now)

US8946281 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2024

(1 year, 2 months from now)

US8541463

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(1 year, 8 months from now)

US8207215

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(1 year, 8 months from now)

US8377982

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2024

(1 year, 8 months from now)

US8008338

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2027

(4 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 30 May, 2003

Treatment: A method of treating or preventing ocular pain and burning/stinging following corneal surgery; A method of treating ocular pain and/or enhancing ocular comfort; A method of treating or reducing ocular pain and burning/stinging; A method of controlling postoperative ocular pain and burning/stinging in a patient; A method of treating or preventing ocular pain and burning; A method of treating ocular pain; A method of treating or preventing ocular pain in a patient

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACULAR LS before it's patent expiration?
More Information on Dosage

ACULAR LS family patents

16

United States

2

Canada

2

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in